SI-BONE Third Quarter 2026 Earnings Call - SI-BONE INC

Explicit Guidance:

• FY2026 Revenue: Reaffirmed guidance of $231 million to $233 million worldwide; midpoint implies >20% year-over-year revenue growth in Q4 2026.
• FY2026 Gross Margin: Maintained guidance of 79%.
• FY2026 Operating Expenses: Reduced growth expectation to 10.5% year-over-year (previously 12%), driven by improved operating leverage.
• FY2027 Revenue Growth: No formal quantitative guidance provided; management expects growth acceleration entering 2027, with a new outlook to be issued in late February 2027 following Q4 results.
• FY2027 Gross Margin: Anticipate modest pressure in 2027 due to non-cash depreciation from new Onyx capacity; long-term expectation for margins to settle around 78% as new platforms launch, though maintaining industry-leading status.
• Operating Leverage (Long-term): Targeted OPEX growth to revenue growth ratio remains 1.25x to 1.75x, with a midpoint expectation of 1.4x–1.5x over the coming years.
• NTAP Timeline: Onyx Alternative Pathway for a New Technology Add-on Payment (NTAP) application submitted; expected to take effect October 1, 2027.
• Proposed CMS Reimbursement (Interventional): Proposal for new office-based CPT-27279 payment ($20,000) and ASC/outpatient payment increases ($16,000/$20,000) if finalized, expected to take effect January 1, 2027.

Business-Segment Outlook:

• Onyx Platform Launch: Alpha launch initiated October 2026; modest contribution expected in Q4 2026, with full launch scheduled for January 2027. Early demand tracking ahead of the Granite launch comparable period.
• Granite Platform: New DRGs for multi-level spinal fusion with pelvic fixation effective October 1, 2026; potential payment increase up to $50,000 per qualifying procedure expected to drive volume and implant utilization (e.g., 4-implant cases vs. 2-implant cases).
• Total Addressable Market (TAM): Estimated at >$650,000 annual procedures globally ($5B market opportunity), combining Granite ($2.5B complex fusion) and Onyx ($1.5B U.S. spinal procedures).
• Physician Base: Targeting expansion to nearly 100 quota-carrying territory managers by end of 2026 (currently 93, with 300 agents); aim to expand from 1,770 active physicians to capture Onyx demand.
• Interventional Spine: Continued acceleration in intra-platform adoption among interventional spine physicians in office-based and ASC settings; viewed as a leading position in SI joint fusion for this cohort.
• Trauma (Smith & Nephew): Joint commercial actions and education programs with Smith & Nephew for TORC/TNT products expected to yield growing adoption during the Q4 trauma season.
• Product Pipeline: Planning to bring additional differentiated technologies to market beyond Onyx in the next few years to address unmet needs in compromised bone.

Market and Competitive Outlook:

• Demand Trends: Observing strong double-digit volume growth (20% in Q3) driven by anatomy-specific solutions for high-risk patients, contrasting with broader industry slowdown concerns.
• Pricing Dynamics: Expected ASP improvement in Q4 2027 driven by Onyx uptake and multi-implant Granite cases; Q4 2026 ASP expected to improve net-net despite lower ASP in interventional settings.
• Market Share: Positioning to capture unmet needs in complex fusion and SI joint dysfunction without direct market share theft, focusing on expanding the total procedure volume addressable to their platform.
• Competitive Advantage: Biomechanical expertise in compromised bone viewed as a moat; Onyx addresses screw loosening (reported in up to 27% of constructs) where traditional screws and bone cement have significant trade-offs.

Macro / Industry Outlook:

• Economic/Demographic Tailwinds: Aging population increasing prevalence of osteoporosis/osteopenia, driving demand for advanced fixation technologies.
• Regulatory: Anticipating final CMS ruling on interventional reimbursement changes in "coming days"; new Granite DRGs already effective Oct 1, 2026.
• Reimbursement Environment: Shift toward favorable reimbursement frameworks for complex spine procedures; NTAP and new DRGs expected to enable patient access and support higher-cost technologies.
• Site of Care: Structural shift toward office-based and ASC procedures for SI joint dysfunction, supported by proposed payment increases for these settings in 2027.

Strategic Initiatives:

• Commercial Expansion: Deployment of additional surgical capacity in November and December 2026; full Onyx rollout beginning January 2027.
• R&D and Manufacturing: Investment in R&D personnel and internal machining capabilities to support cadence of new product launches; cost reduction initiatives ongoing to offset new product depreciation.
• Clinical Data Strategy: Launching a prospective multi-center clinical study for Onyx to evaluate safety and performance; leveraging existing benchtop and animal data while building 2-5 year long-term outcome dossiers.
• Partnerships: Deepening collaboration with Smith & Nephew for trauma awareness; leveraging existing agent networks for global expansion.
• Operational Efficiency: Hybrid sales model (direct + third-party agents) to optimize coverage and productivity; focus on setting up loaner operations to drive high instrument utilization.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Pending finalization of CMS proposed reimbursement changes for interventional spine procedures.
• Margin Pressure: Near-term gross margin compression in 2027 anticipated due to non-cash depreciation costs associated with new Onyx capacity and subscale nature of new product launches.
• Adoption Timing: Potential delay in physician adoption of Onyx if clinical outcome data requirements extend beyond typical 6-12 month window.
• Macro/Industry: Unspecified broader industry procedure volume headwinds, though management views their specific segment as insulated due to unmet clinical needs.
• Competitive Landscape: Risk of competitors addressing the upper/lower spine failure points (screw loosening) previously targeted by Onyx.

Management Tone on the Future:

• Confidence: Highly confident in "defining moment" status for the company, citing convergence of market expansion, favorable reimbursement, and engaged physician base.
• Acceleration: Describes Q4 2026 and 2027 as a "building block" for the "strongest foundation for growth acceleration in the history of the company."
• Prudence: Maintains a "thoughtful and prudent" approach to guidance, preferring to provide specific 2027 numbers after Q4 performance is realized and planning processes complete.
• Strategic Focus: Emphasis on "durable long-term growth" rather than short-term volume spikes; commitment to operating leverage despite growth-oriented investments.

Miscellaneous:

• Product Designation: Onyx received FDA 510K clearance in September 2026 and its third FDA Breakthrough Device Designation.
• Clinical Trials Reference: Management cited the "Sylvia trial" (reducing new-onset SI joint pain from 8.5% to 1.1%) and "PAULA study" (3.3% pelvic fixation failure rate vs. 23.7% historical) as evidence of platform efficacy.
• Financial Flexibility: Cash and equivalents of $146.3 million; operating cash flow generation improved $6.8 million year-over-year to $4.4 million in the trailing 12 months.